Avelios Medical closes funding round to digitize German hospitals

November 2, 2021

  • The 2 million Euro financing round is led by Revent, further investors are High-Tech Gründerfonds and renowned business angels
  • The Munich-based startup digitizes workflows in hospitals with innovative software and enables data-driven patient care

Munich, November 2, 2021 – Avelios Medical, a modular software platform for the digitization of workflows in hospitals and data-driven patient care, has closed a seed funding round of 2 million Euro from Revent, High-Tech Gründerfonds and the founders of Amboss and Oviva.

To address the lack of digitization in healthcare, Avelios has developed a modular software platform that digitizes and optimizes processes in hospitals with state-of-the-art software in a user-friendly way. For example, Avelios’ outpatient and ward module digitize all workflows and enable a fully digital documentation of patient care with innovative features such as an automatically generated doctor’s letter or intelligent input fields.

The company will use the fresh capital to further accelerate the ongoing rollout of the Avelios software in various hospitals as well as the development of additional software modules.

Avelios Medical was founded in 2020 by Nicolas Jakob, Dr. Sebastian Krammer and Christian Albrecht with the vision of becoming the leading software platform for the data-driven digitization of patient care.

AI can fundamentally improve healthcare, but only based on structured data that currently does not exist. Avelios is deliberately digitizing patient care in a way that precisely this missing structured data can be automatically generated and its full potential realized.

Nicolas Jakob, Co-Founder Avelios Medical

Digitizing healthcare to improve patient care is more necessary than ever, and hospitals often lag particularly far behind when it comes to digital workflows and the use of modern software. This leads to extremely inefficient processes, disconnected legacy systems, and a complete lack of useful digital data.

The frustration with incredible inefficiencies and inadequate software solutions that I’ve experienced as a physician myself is the biggest motivation to continually develop software that solves this big problem.

Dr. Sebastian Krammer, Co-Founder Avelios Medical

In addition to the fundamental digitization of workflows, the innovative Avelios software automatically generates fully structured treatment data. This enables data-driven research, business intelligence and billing, as well as the direct integration of AI algorithms to exploit enormous, previously untapped potential. In addition, the modular platform approach enables flexible interfaces to existing legacy systems as well as the integration of modern software solutions and devices.

It’s unbelievable that something as important and big as healthcare has such dramatic deficits in digitization. Our mission is to become the digital backbone of hospitals and enable data-driven healthcare.

Christian Albrecht, Co-Founder Avelios Medical

Added value for hospitals

The Avelios software offers several concrete benefits for hospitals. Digitized workflows and a fast, complete documentation significantly increase process efficiency and employee and patient satisfaction. A low implementation effort, complete modularity and interoperability, and continuous updates are further very attractive for IT departments in hospitals. The software is already successfully in use in the outpatient clinic and laboratory at the LMU Klinikum in Munich, and Avelios is currently rolling out its solution in other hospitals and departments.

We see enormous potential in Avelios to fundamentally improve the quality of treatment in hospitals. The unique modular software platform enables hospitals to build a modern and scalable IT infrastructure without implementation effort.

Henrik Große Hokamp, Partner Revent

In many hospitals processes are still pen- and paper based. We believe that the digital revolution in hospitals will accelerate and that the strong Avelios team has what it takes to become a major player in this field.

Daniela Bach, Senior Investment Manager at High-Tech Gründerfonds

from left to right: Dr. Sebastian Krammer, Christian Albrecht, Nicolas Jakob, Co-Founders Avelios Medical (Picture: Avelios Medical)

About Avelios Medical
Avelios Medical offers a modular software platform for the digitization of workflows in hospitals and data-driven patient care. The state-of-the-art software digitizes and optimizes all workflows in hospitals in a user-friendly manner, offering numerous innovative functions such as an automatically generated doctor’s letter or intelligent input fields for the documentation of patient treatment. In addition, the software automatically generates fully structured data, enabling the direct use of data-driven use cases and AI algorithms. The company is based in Munich and was founded in 2020 by Nicolas Jakob, Dr. Sebastian Krammer and Christian Albrecht.

Media contact
Avelios Medical GmbH
Christian Albrecht

About Revent
Founded in 2020, the Berlin-based VC fund invests across Europe in startups with a clear purpose, using technology to drive systemic change in the areas of climate, health and economic empowerment. The Revent team believes that tomorrow’s best companies will emerge where today’s greatest environmental and societal challenges lie.

About High-Tech Gründerfonds
High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 650 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected more than EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has also successfully sold interests in more than 140 companies.
Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, Deutsche Post DHL, Dräger, 1+1 AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 – 82300 – 188

Investor Contact
High-Tech Gründerfonds Management GmbH
Daniela Bach, Senior Investment Manager
T.: +49 175 2525531

More Press posts

18. January 2022

PreOmics Announces Early Investors’ Exit and Closing of Series B Financing to Accelerate R&D and Commercialization of Proteomics Tools and Consumables

PreOmics Offers Unique Technologies, Advanced Automation Solutions and High-Performance Consumables for the Homogenization, Enrichment and Proteomic Sample Preparation of Biopsy, Tissue, Cell Line and Plasma Samples in Unbiased, Deep Proteomics for Pharmaceutical and Clinical Research MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer of innovative automation and sample preparation tools and consumables for unbiased, deep proteomics analysis
12. January 2022

Berlin-based Fintech Banxware raises EUR 10m to expand its embedded Business Lending solution

Banxware is a lending-as-a-service provider for Embedded Financial Services that enables digital platforms such as marketplaces, payments providers, and other aggregators to offer embedded lending products such as white label merchant cash advance. Element Ventures, D4 Ventures and FinVC as well as Banxwares strategic partner Varengold Bank AG are new investors, joined by all of the existing
12. January 2022

CereGate, the preeminent Computer-Brain-Interface Software Platform, advances in clinical development and secures financing from leading deep tech and mental health investors 468 Capital and re.Mind Capital

In the thriving field of neuroscience, CereGate is poised to revolutionize the treatment of neurological disorders by interacting with the human brain through a unique software-first approach. After making strides in the clinical development, including FDA Breakthrough designation for its first application in Deep Brain Stimulation Freezing of Gait Therapy (FOG-LIGHTS) and launching a clinical trial in the US, CereGate achieves additional funding to further accelerate the development of n